Getinge Year End Report 2021: "Healthy order growth, improved EBITA margin and strong cash flow"
Getinge reported a 6.4% increase in organic order intake for Q4 2021, driven by growth across all business areas. However, net sales declined 9.6% compared to Q4 2020 due to fewer ICU ventilator deliveries. The company maintained a strong demand for ECMO therapy products, and Surgical Workflows showed solid margin expansion. Getinge's adjusted gross profit was SEK 4,150 M with a margin of 52.0%. For the full year 2022, organic sales growth is expected to range between 4-6%.
- Order intake rose 6.4% in Q4 2021.
- Adjusted EBITA margin improved to 21.6%.
- Net sales decreased 9.6% in Q4 2021.
- Cash flow after net investments fell to SEK 1,313 M from SEK 2,283 M.
GOTHENBURG, Sweden, Jan. 28, 2022 /PRNewswire/ -- "The organic order intake increased
As expected, Getinge's net sales declined compared with Q4 2020 which saw large deliveries of ICU ventilators. Demand for products for life supporting ECMO therapy and Sterile Transfer remains strong, while other parts of the operations are demonstrating a stable recovery. In particular, this applies to Surgical Workflows, which also displayed robust margin expansion. Sales of products for planned cardiovascular procedures also increased despite continuing challenges related to COVID-19.
"We are continuing to implement our strategy - focusing on our most attractive growth areas", says Mattias Perjos, President & CEO at Getinge. "An example of this is the acquisition of Talis Clinical, a US-based leading innovator of High Acuity cloud-based software solutions. Talis' offering is the perfect complement to our strong offering in surgery, critical care support and ECMO therapy."
Improvements to the operations are continuing to generate effects in the form of a high EBITA margin and strong cash flows, meaning that Getinge is consolidating its solid financial position and also have scope for attractive acquisitions.
Getinge expects the organic sales growth to be in the upper part of the range of 4
October - December 2021 in brief
- The order intake increased organically by
6.4% and net sales declined organically by9.6% .
- Adjusted gross profit amounted to SEK 4,150 M (4,556) and the gross margin was
52.0% (51.5).
- Adjusted EBITA amounted to SEK 1,723 M (1,817) and the EBITA margin was
21.6% (20.6).
- Adjusted earnings per share amounted to SEK 4.54 (4.58).
- Cash flow after net investments amounted to SEK 1,313 M (2,283)
- After the end of the quarter: Elin Frostehav was appointed President Acute Care Therapies and Eric Honroth President Life Science, starting April 1, 2022.
January - December 2021 in brief
- The order intake declined organically by
3.0% and net sales declined organically by4.8% .
- Adjusted gross profit amounted to SEK 14,392 M (15,874) and the gross margin was
53.2% (53.2).
- Adjusted EBITA amounted to SEK 5,212 M (5,724) and the EBITA margin amounted to
19.3% (19.2).
- Adjusted earnings per share amounted to SEK 13.22 (14.43).
- Cash flow after net investments amounted to SEK 5,946 M (6,207).
- A dividend of SEK 4.00 (3.00) per share is proposed.
Phone Conference
A conference call will be held on January 28, 2022, at 10:00-11:00 am CET hosted by Mattias Perjos, President & CEO, and Lars Sandström, CFO. Please see dial in details below to join the conference:
SE: +46 850 558 357
UK: +44 333 300 92 60
US: +1 646 722 49 03
During the conference call a presentation will be held. To access the presentation through webcast, please use this link: https://tv.streamfabriken.com/getinge-q4-2021
Alternatively, use the following link to download the presentation:
https://www.getinge.com/int/about-us/investors/reports-presentations/
Agenda
09:45 Dial in to the conference
10:00 Presentation
10:30 Q&A
11:00 End of conference
Recording available for 3 years
A recorded version can be accessed for 3 years via https://tv.streamfabriken.com/getinge-q4-2021
Media contact:
Lars Mattson, Head of Investor Relations
Phone: +46 (0)10 335 0043
Email: lars.mattsson@getinge.com
This information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on January 28, 2022, at 08:00 am CET.
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Getinge Year End Report January-December 2021 | |
Mattias Perjos | |
https://mb.cision.com/Public/942/3493490/b0500b9b3f39a8b8.pdf | Press release Getinge FY 2021 Report |
View original content:https://www.prnewswire.com/news-releases/getinge-year-end-report-2021-healthy-order-growth-improved-ebita-margin-and-strong-cash-flow-301470449.html
SOURCE Getinge
FAQ
What was Getinge's order intake growth for Q4 2021?
How did Getinge's net sales perform in Q4 2021?
What is Getinge's expected organic sales growth for full-year 2022?
What were Getinge's adjusted EBITA and gross profit for Q4 2021?
